GURUFOCUS.COM » STOCK LIST » USA » NYSE » Perrigo Co PLC (NYSE:PRGO) » Definitions » ROE %
Switch to:

Perrigo Co ROE %

: -0.19% (As of Mar. 2022)
View and export this data going back to 1991. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Perrigo Co's annualized net income attributable to common stockholders for the quarter that ended in Mar. 2022 was $-10 Mil. Perrigo Co's average Total Stockholders Equity over the quarter that ended in Mar. 2022 was $5,128 Mil. Therefore, Perrigo Co's annualized ROE % for the quarter that ended in Mar. 2022 was -0.19%.

The historical rank and industry rank for Perrigo Co's ROE % or its related term are showing as below:

PRGO' s ROE % Range Over the Past 10 Years
Min: -48.18   Med: 2.09   Max: 23.76
Current: -2.06

During the past 13 years, Perrigo Co's highest ROE % was 23.76%. The lowest was -48.18%. And the median was 2.09%.

PRGO's ROE % is ranked worse than
62.12% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 3.93 vs PRGO: -2.06

Perrigo Co ROE % Historical Data

The historical data trend for Perrigo Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perrigo Co Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.97 2.21 2.55 -2.84 -1.28

Perrigo Co Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.72 -4.17 -4.41 0.74 -0.19

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Perrigo Co ROE % Distribution

For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's ROE % distribution charts can be found below:

* The bar in red indicates where Perrigo Co's ROE % falls into.



Perrigo Co ROE % Calculation

Perrigo Co's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=-68.9/( (5655.1+5151.7)/ 2 )
=-68.9/5403.4
=-1.28 %

Perrigo Co's annualized ROE % for the quarter that ended in Mar. 2022 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Mar. 2022 )/( (Total Stockholders Equity (Q: Dec. 2021 )+Total Stockholders Equity (Q: Mar. 2022 ))/ count )
=-9.6/( (5151.7+5104.5)/ 2 )
=-9.6/5128.1
=-0.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Perrigo Co  (NYSE:PRGO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Mar. 2022 )
=Net Income/Total Stockholders Equity
=-9.6/5128.1
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-9.6 / 4298)*(4298 / 10407.6)*(10407.6 / 5128.1)
=Net Margin %*Asset Turnover*Equity Multiplier
=-0.22 %*0.413*2.0295
=ROA %*Equity Multiplier
=-0.09 %*2.0295
=-0.19 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Mar. 2022 )
=Net Income/Total Stockholders Equity
=-9.6/5128.1
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (-9.6 / -52) * (-52 / 101.2) * (101.2 / 4298) * (4298 / 10407.6) * (10407.6 / 5128.1)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.1846 * -0.5138 * 2.35 % * 0.413 * 2.0295
=-0.19 %

Note: The net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Perrigo Co ROE % Related Terms

Thank you for viewing the detailed overview of Perrigo Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Perrigo Co Business Description

Perrigo Co logo
Address
The Sharp Building, Hogan Place, Dublin, IRL, D02 TY74
Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company's product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestitures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma.
Executives
Ives Alison officer: EVP & Chief Scientific Officer C/O PERRIGO COMPANY PLC 515 EASTERN AVENUE ALLEGAN MI 49010
Hanson Kyle officer: EVP & General Counsel
Bezerra Eduardo Guarita officer: EVP & Chief Financial Officer C/O FRESH DEL MONTE PRODUCE INC. PO BOX 149222 CORAL GABLES FL 33134
Ashford Orlando D director C/O AMERANT BANK 220 ALHAMBRA CR. CORAL GABLES FL 33134
Doyle Katherine C. director 100 ABBOTT PARK ROAD, AP6C-1N D032L ABBOTT PARK IL 60064
Sorota Richard S officer: EVP & President CSCA HARMAN INTERNATIONAL INDUSTRIES, INC. 1101 PENNSYLVANIA AVE, NW, #1010 WASHINGTON DC 20004
Mann Erica L director ONE KELLOGG SQUARE P.O. BOX 3599 BATTLE CREEK MI 49016-3599
Silcock Raymond officer: EVP, Chief Financial Officer 399 JEFFERSON ROAD PARSIPPANY NJ 07054
Willis Robert officer: Acting CHRO C/O PERRIGO COMPANY PLC 515 EASTERN AVENUE ALLEGAN MI 49010
Dillard James E Iii officer: EVP, Chief Scientific Officer 6601 WEST BROAD STREET RICHMOND VA 23230
Kessler Murray S director, officer: CEO 714 GREEN VALLEY ROAD GREENSBORO NC 27408
Smith Jeffrey C director 777 THIRD AVENUE, 18TH FLOOR NEW YORK NY 10017
Roehrhoff Uwe director, officer: CEO C/O PERRIGO COMPANY PLC TREASURY BUILDING, LOWER GRAND CANAL ST DUBLIN L2 D2
Classon Rolf A director C/O CATALENT, INC. 14 SCHOOLHOUSE ROAD SOMERSET NJ 08873
Karaboutis Adriana director C/O BIOGEN IDEC INC. 225 BINNEY ST. CAMBRIDGE MA 02142

Perrigo Co Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)